English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
Urdu
Colorectal cancer (CRC) is a heterogeneous disease that occurs in the colon and the rectum, parts of the gastrointestinal system. CRC is the third leading cause of cancer-related death worldwide. The incidence and mortality of CRC is expected to increase significantly in the future, with more than 2.2 million new cases and 1.1 million deaths expected by 2030.
Metastasis is the leading cause of death in CRC patients, especially liver metastasis. According to previous studies, about 25% of CRC cases are clinically diagnosed with liver metastases in early stages, and about 50% of CRC patients experience symptoms of liver metastases throughout the course of the disease. Differential presence of exons (DPE) by next generation sequencing (NGS) is an innovative method to analyze the complete exome sequence and can be used as a stratification and predictive tool in patients with colorectal cancer (CRC).
In this editorial, researchers David Rubio-Mangas, Mariano García-Arranz, Javier Suela and Damian GarcíaOlmo from Instituto de Investigación Sanitaria Fundación Jiménez Díaz, Universidad Autónoma de Madrid and Hospital Fundación Jiménez Díaz discuss DPE analysis as an emerging and promising technique in the field of liquid biopsy that has the advantage of being non-invasive compared to invasive diagnostic techniques. In addition, this analysis can provide valuable information on CRC progression and could provide information on response to therapy.
“The use of liquid biopsy in clinical practice may also reduce the costs and time required for staging CRC patients, which could have implications for diagnosis and treatment [12, 13].”
Continue Reading the Editorial: https://www.oncoscience.us/article/573/
Keywords: whole-exome sequencing, NGS, cell-free DNA, DPE, differential presence of exons
About Oncoscience:
Oncoscience is a peer-reviewed, open-access, traditional journal covering the rapidly growing field of cancer research, especially emergent topics not currently covered by other journals. This journal has a special mission: Freeing oncology from publication cost. It is free for the readers and the authors.
To learn more about Oncoscience, visit Oncoscience.us and connect with us on social media:
Oncoscience Journal Office
6666 East Quaker Str., Suite 1D
Orchard Park, NY 14127
Phone: 1-800-922-0957, option 4
###
